SAN DIEGO, June 28, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (HALO) announced today that Roche received a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for the subcutaneous formulation of Herceptin® (trastuzumab) using Halozyme's recombinant human hyaluronidase (rHuPH20) for the treatment of patients with HER2-positive breast cancer in Europe. (Logo; http://photos.prnewswire.com/prnh/20100302/LA63139LOGO) Roche's pivotal Phase 3 HannaH study, conducted in 102 sites outside the US, demonstrated that Herceptin SC may help decrease the time patients spend receiving treatment at a hospital or physician's practice, by...
↧
